Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Xenon ( (XENE) ) is now available.
Xenon Pharmaceuticals Inc. announced that it will report its fourth-quarter and full-year 2024 financial results on February 27, 2025. This announcement highlights the company’s ongoing commitment to transparency with its stakeholders, as it continues to make strides in the biopharmaceutical industry with its innovative therapeutics portfolio. The report could provide insights into the company’s financial health and its strategic positioning within the market.
More about Xenon
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that specializes in discovering, developing, and delivering life-changing therapeutics. The company is advancing an ion channel product portfolio to address high unmet medical needs, particularly in the areas of epilepsy and depression. Their most advanced product is Azetukalner, a selective Kv7 potassium channel opener in late-stage clinical development for multiple indications.
YTD Price Performance: -4.16%
Average Trading Volume: 409,780
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $2.98B
Find detailed analytics on XENE stock on TipRanks’ Stock Analysis page.
